Viewing Study NCT04135495


Ignite Creation Date: 2025-12-24 @ 2:22 PM
Ignite Modification Date: 2026-01-24 @ 4:11 AM
Study NCT ID: NCT04135495
Status: COMPLETED
Last Update Posted: 2022-11-22
First Post: 2019-08-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
Sponsor: Eloxx Pharmaceuticals, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cystic Fibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cystic fibrosis View
None ELX-02 View
None G542X allele View
None eukaryotic ribosomal selective glycoside View